|
|
 |
|
Viewing report
|
|
|
|
Women's Health Series: Endometriosis--How Will New Therapies Compare with Current Market Leaders?
Decision Resources, Inc., Sep 2008, Pages: 20
This report, along with the other reports in the Women’s Health Series, includes primary research with thought-leading clinicians. We conducted an in-depth survey with obstetricians/gynecologists who have expertise in treating endometriosis. In this report, you will find their opinions on current and emerging therapies, and on treatment approaches to endometriosis.
Endometriosis is the cause of chronic pain and potential infertility for many women. However, no new agent to treat the disease has emerged in more than ten years, and the most common treatments employ mechanisms of action that have been available for several decades. Furthermore, these treatments have significant drawbacks, most notably the loss of bone density and numerous menopause-like side effects. New agents in development may alleviate some of these problems with existing therapies and use this advantage to establish a position in the market.
Get the Answers You Need to Shape Your Strategy
- Endometriosis affects millions of women in the United States. What are the most common sites for endometrial lesions? What are the symptoms and complications of endometriosis? How does disease severity affect the level of symptoms?
- No new agent has been approved for the treatment of endometriosis in more than ten years. What are the most commonly prescribed agents for the treatment of endometriosis? How does treatment change with increasing disease severity? What are the strengths and drawbacks of existing treatments?
- Many existing treatments have a negative side-effect profile. What agents are currently in development for endometriosis? How do those treatments improve upon existing treatments? Are there opportunities for endometriosis agents in the treatment of other diseases?
Scope
Overview of endometriosis: etiology and pathophysiology, symptoms, disease severity.
- Current treatments for endometriosis: Sanofi -Aventis’s Danocrine, Abbott Laboratories’/Takeda Pharmaceutical’s/TAP Pharmaceutical’s Lupron/Lupron Depot, AstraZeneca’s Zoladex, Pfi zer’s Synarel, Pfizer’s Provera/Depo-Provera, surgical options.
- Medical practice: U.S. specialists surveyed to determine current prescribing patterns for various stages of endometriosis.
- Emerging treatments: a review of the endometriosis pipeline, Neurocrine Biosciences’ Elagolix, Repros Therapeutics’ Proellex (CDB-4124), KV Pharmaceuticals’ FP-1096.
- Outlook for the endometriosis market: 2007 market, expansion opportunities for endometriosis agents, outlook for emerging agents.
- Women’s Health Series: In 2007, the market for women’s reproductive health exceeded $23 billion worldwide. In the Women’s Health Series, we examine three specific markets, focusing on areas of unmet need and the best marketing strategies to ensure adoption of a new agent. We will provide insight from a variety of thought leaders on the current state of disease treatment and their opinions on the most promising agents currently in the pipeline.
Also available
Womens Health Series: Is There Change Ahead for the Female Infertility Market?
Customers who bought this item also bought
Stakeholder Opinions: Endometriosis - Scientific clarity will unlock market potential
Strategic Perspectives 2002: Endometriosis
European Endometriosis Therapeutics Market
Endometriosis For Dummies
Endometriosis - Growing the Patient Population is Key to Unlocking the Markets Commercial Potential
Womens Health Endometriosis
Endometriosis Pipeline Forecast
Opportunities in Menopausal Treatments: Will New Therapies Overtake Hormone Replacement?
Women's Health Series: Is There Change Ahead for the Female Infertility Market?
Endometriosis Therapy Area Pipeline Report
Autoimmune Disease Series: Will Biologics Emerge as New Treatments for Reactive Arthritis?
Psoriasis - Biologics are Yet to Make Topical Treatments Obsolete
|
|
|
|
